YY001

BIOLOGICAL2 trials

Sponsors

Chongqing Claruvis Pharmaceutical Co., Ltd., Shanghai Yuyao Biotech Co., Ltd.

Conditions

Advanced Solid TumorModerate to Severe Glabellar Lines

Phase 1

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

CompletedNCT05743634

Chongqing Claruvis Pharmaceutical Co., Ltd.Moderate to Severe Glabellar Lines

Start: 2022-03-22End: 2023-02-13Updated: 2023-02-24

An Phase I Study of YY001 in Patients with Advanced Solid Tumors

CompletedNCT06228846

Shanghai Yuyao Biotech Co., Ltd.Advanced Solid Tumor

Start: 2022-07-14End: 2024-05-30Updated: 2025-01-03

Related Papers

An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-01